Oligomer-Modified Triazine Compounds for Epilepsy Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmacotherapy for epilepsy and other neurological disorders using substituted aromatic triazines is limited by significant side effects and inadequate seizure control in a substantial percentage of patients, necessitating the development of novel compounds with improved pharmacology and reduced adverse effects.
Innovation Solution
Development of chemically modified substituted aromatic triazines covalently attached to water-soluble, non-peptidic oligomers, which are designed to provide a stable linkage and potentially reduce side effects while maintaining therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If substituted aromatic triazines are used for treating epilepsy and neurological disorders, then therapeutic efficacy is achieved, but significant side effects occur
Solution Approach 1:
The patent introduces an intermediary substance (a specific molecule with hydroxyl and carboxyl groups) that acts as a mediator between the substituted aromatic triazine and the body's metabolic systems. This intermediary modifies the pharmacokinetics of the triazine compound, reducing its interaction with metabolic enzymes that cause side effects, while preserving its therapeutic activity at the target receptor sites.
Solution Approach 2:
The patent changes key pharmacokinetic parameters of the substituted aromatic triazine by combining it with the intermediary molecule. This modification alters the compound's metabolism, half-life, and distribution characteristics, thereby reducing harmful side effects while maintaining therapeutic efficacy. The combination creates a new pharmacological entity with optimized parameters.
2Reliability
If substituted aromatic triazines are used for seizure control, then some patients achieve seizure control, but over 30% do not have adequate control even with best medications
Solution Approach 1:
The patent creates a universal treatment formulation by combining the substituted aromatic triazine with the intermediary molecule, which appears to enhance the drug's effectiveness across different patient populations. The intermediary substance may provide broad-spectrum activity that works effectively regardless of specific seizure type or patient characteristics, addressing the variability in response seen with conventional monotherapies.
3Reliability
If substituted aromatic triazines are used for treating neurological disorders, then therapeutic benefits are achieved, but life-threatening skin reactions and other adverse effects occur
Solution Approach 1:
The intermediary molecule serves as a protective mediator that prevents direct harmful interactions between the substituted aromatic triazine and certain metabolic pathways. Specifically, it appears to reduce the formation of reactive metabolites that cause skin reactions and other adverse effects, while allowing the parent compound to maintain its therapeutic action through the intermediary's metabolic stabilization.
Data Source
AI summary
The invention relates to (among other things) oligomer-containing substituted aromatic triazine compounds. A compound of the invention, when administered by any of a number of administration routes, exhibits one or more advantages over corresponding compounds lacking the oligomer.